UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome

Clinical journal of the American Society of Nephrology, 2017-04, Vol.12 (4), p.700-710

2017

Volltextzugriff (PDF)

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

Journal of the American Society of Nephrology, 2017-04, Vol.28 (4), p.1023-1039

2017

Volltextzugriff (PDF)

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

Kidney international, 2020-04, Vol.97 (4), p.631-635

2020

Volltextzugriff (PDF)

SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function

Clinical journal of the American Society of Nephrology, 2022-05, Vol.17 (5), p.663-671

2022

Volltextzugriff (PDF)

Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function

Diabetes care, 2020-01, Vol.43 (1), p.228-234

2020

Volltextzugriff (PDF)

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes

Clinical science (1979), 2020-12, Vol.134 (23), p.3107

2020

Volltextzugriff (PDF)

Understanding EMPA-REG OUTCOME

The lancet. Diabetes & endocrinology, 2015-12, Vol.3 (12), p.928-929

2015

Volltextzugriff (PDF)

Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function

American journal of physiology. Renal physiology, 2021-06, Vol.320 (6), p.F1152-F1158

2021

Volltextzugriff (PDF)

The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well‐controlled plasma LDL cholesterol

Diabetes, obesity & metabolism, 2020-06, Vol.22 (6), p.988-996

2020

Volltextzugriff (PDF)

Whole-body insulin clearance in people with type 2 diabetes and normal kidney function: Relationship with glomerular filtration rate, renal plasma flow, and insulin sensitivity

Journal of diabetes and its complications, 2022-04, Vol.36 (4), p.108166-108166, Article 108166

2022

Volltextzugriff (PDF)

Kidney hemodynamic profile and systemic vascular function in adults with type 2 diabetes: Analysis of three clinical trials

Journal of diabetes and its complications, 2022-03, Vol.36 (3), p.108127-108127, Article 108127

2022

Volltextzugriff (PDF)

Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes

The lancet. Diabetes & endocrinology, 2016-03, Vol.4 (3), p.188-189

2016

Volltextzugriff (PDF)

The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial

Bone (New York, N.Y.), 2018-07, Vol.112, p.173-176

2018

Volltextzugriff (PDF)

Exposure-Response Analysis of the Sodium-Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes

Journal of personalized medicine, 2023-04, Vol.13 (5), p.747

2023

Volltextzugriff (PDF)

Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function

Kidney international reports, 2023-04, Vol.8 (4), p.916-920

2023

Volltextzugriff (PDF)

Renoprotection in LEADER and EMPA-REG OUTCOME

The lancet. Diabetes & endocrinology, 2016-10, Vol.4 (10), p.812-814

2016

Volltextzugriff (PDF)

Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 Inhibitors

Kidney international reports, 2020-11, Vol.5 (11), p.2052-2054

2020

Volltextzugriff (PDF)

Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross‐sectional study

Microcirculation (New York, N.Y. 1994), 2021-08, Vol.28 (6), p.e12700-n/a

2021

Volltextzugriff (PDF)

The development of polycythemia vera after phlebotomy treatment for hereditary haemochromatosis

EJHaem, 2021-08, Vol.2 (3), p.537-538

2021

Volltextzugriff (PDF)

The authors reply

Kidney international, 2020-04, Vol.97 (4), p.806

2020

Volltextzugriff (PDF)

Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease

Diabetologia, 2017-05, Vol.60 (5), p.927-937

2017

Volltextzugriff (PDF)

Extracellular Volume and Plasma Potassium Determine Urinary Prostaglandin E2 Excretion in Kidney Disease: PO1454

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.467-467

2020

Volltextzugriff (PDF)

250-OR: Beta-Cell Rest Induced by Dapagliflozin Improves ß-Cell Secretory Capacity in Type 2 Diabetes Patients: A Randomized Controlled Trial vs. Gliclazide

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

243-OR: ADA Presidents' Select Abstract: Dapagliflozin Reduces Measured GFR by Reducing Renal Efferent Arteriolar Resistance in Type 2 Diabetes

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(72)
Japanisch
(3)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function

Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes

Understanding EMPA-REG OUTCOME

Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function

The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well‐controlled plasma LDL cholesterol

Whole-body insulin clearance in people with type 2 diabetes and normal kidney function: Relationship with glomerular filtration rate, renal plasma flow, and insulin sensitivity

Kidney hemodynamic profile and systemic vascular function in adults with type 2 diabetes: Analysis of three clinical trials

Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes

The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial

Exposure-Response Analysis of the Sodium-Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes

Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function

Renoprotection in LEADER and EMPA-REG OUTCOME

Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 Inhibitors

Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross‐sectional study

The development of polycythemia vera after phlebotomy treatment for hereditary haemochromatosis

The authors reply

Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease

Extracellular Volume and Plasma Potassium Determine Urinary Prostaglandin E2 Excretion in Kidney Disease: PO1454

250-OR: Beta-Cell Rest Induced by Dapagliflozin Improves ß-Cell Secretory Capacity in Type 2 Diabetes Patients: A Randomized Controlled Trial vs. Gliclazide

243-OR: ADA Presidents' Select Abstract: Dapagliflozin Reduces Measured GFR by Reducing Renal Efferent Arteriolar Resistance in Type 2 Diabetes

Suchergebnisse filtern